Diabetes prevalence in older people is increasing and older people have an increased risk of hypoglycemia. Results are shown here of subgroup analyses in adults aged ≥65 years (pre-planned) and ≥70 years (post hoc) of the BRIGHT study in insulin-naïve adults with T2DM.

Between treatment groups, baseline characteristics were similar; expected differences were observed between age subgroups: diabetes duration was longer, renal function was worse and BMI slightly lower in the ≥65 and ≥70 years groups vs. the overall population (Table).

HbA1c reductions from baseline to week 24 were similar between treatment groups in the overall and ≥65 years populations. Heterogeneity of treatment effect was seen across the </≥70 years subgroups (p=0.0087); HbA1c reduction in both treatment arms was similar in those <70 years but greater with Gla-300 vs. IDeg-100 in those ≥70 years. Incidence and rates of hypoglycemia at week 24 were similar between treatment groups in all populations assessed. Insulin dose increase was slightly greater with Gla-300 vs. IDeg-100 in the overall and ≥65 years populations, but similar in both treatment groups in the ≥70 years subgroup.

Gla-300 provided similar HbA1c reduction vs. IDeg-100 in older people with T2DM, and greater reductions vs. IDeg-100 in those aged ≥70 years with no increased hypoglycemia risk in this frail population.

graphic
View largeDownload slide
Disclosure

B. Charbonnel: Consultant; Self; AstraZeneca, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier. Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Takeda Pharmaceutical Company Limited. V.R. Aroda: Consultant; Self; ADOCIA, AstraZeneca, Becton, Dickinson and Company, Novo Nordisk Inc., Sanofi, Zafgen, Inc. Employee; Spouse/Partner; Merck & Co., Inc. Research Support; Self; AstraZeneca, Calibra Medical, Eisai Inc., Janssen Research & Development, Novo Nordisk Inc., Sanofi, Theracos, Inc. J. Westerbacka: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. F. Lauand: Employee; Self; Sanofi. E. Boelle: Employee; Self; Sanofi Research & Development. A.Y. Cheng: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, HLS Therapeutics, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; Boehringer Ingelheim International GmbH, Sanofi. Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., mdBriefCase Group Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Melior Pharmaceuticals, Inc., Bukwang Pharm. Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc. Other Relationship; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. G.B. Bolli: Advisory Panel; Self; Sanofi. Research Support; Self; A. Menarini Diagnostics, Medtronic.

Funding

Sanofi (NCT02738151)

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.